ribosomal protein S4X pseudogene 23Genealiases: []
Q-omics provides the consensus-scored RPS4XP23 profile across patient tissues and cancer cell-line models. RPS4XP23 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPS4XP23 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, RPS4XP23 RNA expression shows 7,387 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where RPS4XP23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS4XP23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS4XP23 survival associations across molecular data types. RPS4XP23 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS4XP23 RNA expression–survival associations across cancer types. High RPS4XP23 expression shows unfavorable associations in LUSC and DLBC, but favorable associations in KIRC, BLCA, UVM and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPS4XP23 RNA expression.
This table summarizes RPS4XP23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS4XP23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS4XP23 shows higher tumor expression in KIRC, KICH, THCA, PAAD, KIRP and CHOL. The KIRC box plot shows higher RPS4XP23 RNA expression in tumor versus normal tissue (log2 FC = +0.166, t-test p < 0.001).
This table shows molecular features associated with RPS4XP23 in patient tissues and cancer cell lines. In patient samples, RPS4XP23 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
